Q/C Technologies, Inc. (QCLS)

Overview

MyMD Pharmaceuticals, Inc., established in 2014 and based in Baltimore, Maryland, represents a pivotal force in the pharmaceutical realm, primarily focusing on the development of novel therapeutic platforms aimed at the intersection of aging, autoimmune diseases, and disorders related to chronic pain, anxiety, and sleep. The company actively engages in the clinical development stage, harnessing innovative approaches to address age-related diseases and the mechanisms of aging itself. Through its dedicated research and development efforts, MyMD Pharmaceuticals stands at the forefront of advancing medical solutions designed to improve quality of life and longevity.

Products and Services

• MYMD-1

  A cornerstone of MyMD Pharmaceuticals' pipeline, MYMD-1, is a clinical stage small molecule that showcases the company's commitment to innovation in immune system regulation. With a focus on pro-inflammatory cytokines, this drug platform is engineered to introduce groundbreaking treatments for autoimmune diseases and illnesses associated with aging. MYMD-1 is under study in a Phase 2 clinical trial targeting a spectrum of conditions including sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. Beyond its primary function, it also harbors potential in addressing inflammation-related depression and anxiety, as well as depression associated with COVID-19.

• Supera-CBD

  In alignment with modern therapeutic demands, MyMD Pharmaceuticals is also pioneering in the development of Supera-CBD, a synthetic analogue of cannabidiol. This innovative compound extends the therapeutic scope to encompass the treatment of epilepsy, pain, and anxiety/depression, reflecting the company's dedication to addressing a broad spectrum of health concerns with cutting-edge solutions.